This is the second layoff announced by the company so far in 2024.

As Dexcom and Abbott both move closer to over-the-counter launches of continuous glucose monitoring sensors, analysts forecast revenue potential for the new category.

In the study, the device will be evaluated relative to technology that has already been FDA approved.

The recall details that the affected kits contain incorrect concentrations of Ceftriaxone antibiotic in two wells.

Are you interested in an upcoming event but unsure how to gain approval? This quick guide is for you.

The deal follows Labcorp, Quest’s rival, becoming the winning bidder to acquire Invitae’s assets.